Worldwide appraisal and update (2010) of telavancin activity tested against a collection of gram-positive clinical pathogens from five continents

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3999-4004

  Mendes, Rodrigo E ^a   Sader, Helio S ^a   Farrell, David J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CENTRAL AMERICA; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EUROPE; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; MEDICAL DEVICE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PACIFIC ISLANDS; PRIORITY JOURNAL; SOUTH AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS FAECALIS;

AMINOGLYCOSIDES; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 84862573643     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00011-12     Document Type: Article

References (16)

1. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Clinical and Laboratory Standards Institute. 2011. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Draghi DC, et al. 2008. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
4. Draghi DC, et al. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST). January 2011. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland. http://www.eucast.org/clinical- breakpoints/.
6. Farrell DJ, Krause KM, Benton BM. 2011. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagn. Microbiol. Infect. Dis. 69:275-279.
7. Gould IM. 2011. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 66(Suppl. 4):iv17-iv21.
8. Higgins DL, et al. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
9. Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG. 2011. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis. 69:342-347.
10. Kosowska-Shick K, et al. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53:4217-4224.
11. Krause KM, et al. 2008. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52:2647-2652.
12. Lunde CS, et al. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53:3375-3383.
13. Mendes RE, Moet GJ, Janechek MJ, Jones RN. 2010. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:2704-2706.
14. Mendes RE, Sader HS, Farrell DJ, Jones RN. 2011. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn. Microbiol. Infect. Dis. 71:93-97.
15. Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN. 2010. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn. Microbiol. Infect. Dis. 67:359-368.
16. Theravance. 2009. Vibativ package insert. Theravance, South San Francisco, CA. http://www.vibativ.com.